方法：被诊断为BRVO继发ME的患者行眼科检查、CMT测量、荧光素血管造影。排除荧光素血管造影出现黄斑缺血患者，其他疾病继发的其他部位新生血管化患者，有眼内治疗史(激光治疗、玻璃体腔注射或眼科手术)患者。CMT >250μm的32例患者给予bevacizumab(Altuzan^®；，0.125mg/0.05mL)注射治疗，并随访12mo。分析最佳矫正视力(BCVA)logMAR数据和CMT控制参数。使用Minitab15.0软件统计分析配对t检验，P<0.05有统计学意义。

结果： BCVA logMAR数据和CMT控制参数的平均值较注射前有明显改变(P<0.01)。平均最佳矫正视力增量为0.477±0.235，平均CMT较注射前下降257.906±88.865。10例(31%)患者对单次注射有阳性反应，平均12.6±0.66mo未复发ME。5例(15.6%)患者接受两次注射，17例(53%)3次以上。单眼平均注射量2.18±0.91(1～4)。第一组ME复发时间为2.45±0.63mo，第二组为2.58±0.66mo，第三组为3.17±0.48mo。5例(15.6%)患者需要多次注射以减轻ME，视力并未随ME的减轻而增加。

结论：玻璃体腔注射bevacizumab是常规治疗BRVO继发ME的方法，有效、快速、安全。为了使疗效持久，需加强后续处理，通过激光或长效药物保持无水肿状态。视网膜静脉循环和ME须通过荧光素血管造影观察，而不能采取频繁注射。是否需再次注射必须根据ME的临床表现和视力的预测来判断。

METHODS:Thirty-two patients who underwent intravitreal bevacizumab(Altuzan^®)0.125mg/0.05mL injection for ME secondary to BRVO at least 12mo follow up period have been studied respectively. Patients with diagnosis of ME secondary to BRVO were applied an ophthalmic examination, CMT measurement, and fluorescein angiography, so patients whose CMT above 250μm were offered intravitreal bevacizumab treatment. Patients who had macular ischemia on fluorescein angiography, neovascularisation elsewhere secondary to other types of diseases, received any intraocular treatment before(such as laser treatment, intravitreal injection or eye surgery)have been out of trial. Data of logMAR best corrected visual acuity(BCVA)and CMT in control visits have been evaluated. For statistical analysis Student's paired t-test was used by Minitab15.0 software and a P-value <0.05 was considered as statistically significant.

RESULTS: Mean logMAR BCVA changes and mean CMT changes were statistically significant compared to pre-injection values at last visit(P<0.01). Mean BCVA increment was 0.477±0.235, mean CMT decline was 257.906±88.865 compared to pre-injection at last visit. Ten(31%)of the patients had a positive response with a single injection and no recurrence of ME for a mean of 12.6±0.66mo. Five(15.6%)patients received injection two times and 17(53%)patients more than 3 injections. Mean injection per eye was 2.18±0.91(1～4)respectively. Recurrence of ME was seen aproximately in 2.45±0.63mo at the first control, 2.58±0.66mo at the second control and 3.17±0.48mo at the third control respectively. Five(15.6%)of the patients needed multiple injections for reducing ME whereas visual acuity gain was not achieved as ME reduced in those patients.

CONCLUSION: Treatment of ME secondary to BRVO with intravitreal bevacizumab seems effective, fast, safe, and commonly performed treatment. In order to achieve this lasting effect, we have to strengthen this post treatment non-edematous status by lasers or long lasting agents. Retinal venous circulation and ME must be observed on fluorescein angiography rather than making frequent injections. Reinjections must be done according to the clinical status of ME and the prediction of visual acuity gain.